Figure 2. Change From Baseline in Urgency Urinary Incontinence Episodes per Day by Treatment Group by Month.

Values in the graph include adjusted mean estimates and associated 95% CIs (indicated by error bars) obtained from the linear mixed model controlling for randomization strata defined by age group (<65 years vs ≥65 years) and site. The number of diaries for each treatment group and month included in the model varies from 151 to 179 for the intention-to-treat population and 122 to 154 for the clinical responder population, but all values from all time points contribute to the mean and interval estimates at each time point. A clinical responder is defined as having 50% or more reduction in mean number of episodes of urgency urinary incontinence on a 3-day bladder diary duringthe 7- to 14-day testing phase for women randomized to receive sacral neuromodulation and 1 month after injection for women randomized to receive onabotulinumtoxinA.